Research progress of trastuzumab emtansine in breast caner
YUAN Yang
ZHANG Shaohua
JIANG Zefei
Abstract：Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate.Through a stable linker, the HER-2 targeting antitumor properties of trastuzumab is conjugated with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).Efficacy has now been demonstrated in randomized trials as first-line, second-line, and later than the second-line treatment of advanced breast cancer.The NCCN panel recommends T-DM1 as a preferred option for treatment of patients with HER2-positive metastatic breast cancer who have previously received a trastuzumab-based regimen.Ongoing studies are also evaluating the use of T-DM1 in neoadjuvant, and adjuvant settings and in combination with other agents.In this article, we review the mechanism of action of T-DM1, efficacy and safety data in critical clinical studies, predictors of response or resistance to T-DM1 and the strategies to overcome resistance, may offer practical reference for clinicians.
Keywords：Breast cancerTrastuzumab emtansineHER-2Antibody-drug conjugate
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 557-561 )